Overview

* Keros Q3 net loss narrows to $7.3 mln from $53 mln, largely due to Takeda license revenue

* Company plans to return $375 mln of excess capital to stockholders

* Research and development expenses decrease as Takeda assumes elritercept costs

Outlook

* Company expects cash to fund operations into first half of 2028

* Takeda plans Phase 3 trial for elritercept in myelodysplastic syndromes

* Keros advancing Phase 2 trial for KER-065 in Duchenne muscular dystrophy

Result Drivers

* TAKEDA LICENSE REVENUE - Revenue from license agreement with Takeda significantly reduced net loss

* R&D EXPENSES DECREASE - Transition of elritercept-related R&D expenses to Takeda lowered costs

* ADMIN EXPENSES INCREASE - External costs increased general and administrative expenses despite reduced headcount

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$7.28

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Keros Therapeutics Inc ( KROS ) is $22.50, about 30.9% above its November 4 closing price of $15.55

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)